Celsion focuses on developing targeted oncology therapies using directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Their lead product candidate, ThermoDox®, is a heat-activated liposomal encapsulation of doxorubicin currently in a phase 3 trial for hepatocellular carcinoma. They also have GEN-1, a DNA-mediated immunotherapy for ovarian cancer. With three platform technologies, Celsion aims to maximize efficacy and minimize side effects in cancer treatments. Their mission is to revolutionize cancer treatment with novel targeting technologies and ultimately cure cancers. Celsion is a fully integrated biotechnology company with a clinical pipeline, platform technologies for nucleic acid-based immunotherapies, and expertise in oncology research and development.